AR031572A1 - Derivados de ribavirina, composiciones farmaceuticas y el uso de los mismos solo o en combinacion para la preparacion de medicamentos para erradicar hcv-arn en pacientes que tienen infeccion cronica de hepatitis c - Google Patents
Derivados de ribavirina, composiciones farmaceuticas y el uso de los mismos solo o en combinacion para la preparacion de medicamentos para erradicar hcv-arn en pacientes que tienen infeccion cronica de hepatitis cInfo
- Publication number
- AR031572A1 AR031572A1 ARP010101840A ARP010101840A AR031572A1 AR 031572 A1 AR031572 A1 AR 031572A1 AR P010101840 A ARP010101840 A AR P010101840A AR P010101840 A ARP010101840 A AR P010101840A AR 031572 A1 AR031572 A1 AR 031572A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nr21r22
- aryl
- alkanoyl
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen derivados de ribavirina, que comprenden un compuesto representado por la formula (1), en la cual: por lo menos uno de R2', R3' o R5' es H, R20-(W)x-CO-, R20-(W)x-CS- o R20-(W)x-PO(OH)-; y donde por lo menos uno de R2', R3' o R5' no es H; donde R20 es alquilo, H, alcanoilo, cicloalquilo, arilo, heterocíclico, NR21R22, alquenilo, o alquinilo; o es alquilo, alcanoilo, alquenilo o alquinilo substituido con halo, fenilo, cicloalquilo, NR21R22, hidroxi, alcoxi; o es arilo substituido con fenilo, halo, CN, NO2, OH, R28, OR28, CF3, SH, SR21, SOR21, SO2R21, NR21R22, CO2H, CO2-, OR21, O-M+ o S-M+; donde M+ es un cation de metal alcalino; o R20 es -(CHR21)e-(CH2)f-CO-R22, -(CHR21)e-(CH2)t-OR22, o -(CHR21)e-(CH2)f-NR21R22; W es O, NR28 o S; R21 es H, alquilo, alcanoilo, Y o arilo o es alquilo, alcanoilo o arilo substituido con halo, fenilo, CN, NO2, OH, CO2H o alcoxi; y R22 es H, alquilo o arilo, o es alquilo o arilo substituido con fenilo; halo, CN, NO2, OH, CO2H o alcoxi; o R21 y R22 tomados conjuntamente con N y uno de CHR21, NR21, O, S, SO o SO2 forman un anillo de cinco, seis o siete miembros; R27 es H, OR21, NR21R22, R20-(W)x-CO-, R20-(W)x-CS-, (HO)2PO- o R20-(W)x-PO(OH)- o HO-SO2; R28 es H, alcanoilo, arilo, alquilo o alquilo substituido con OH, halo o NR21R22; e = 0 a 6; f = 0 a 10; t = 0 a 100; s = 0 a 6000; r = 1 a 5000; y x = 0 o 1; o una sal farmacéuticamente aceptable del mismo, las composiciones farmacéuticas que los contienen así como también el uso de los derivados de ribavirina representados por la formula (1) para la preparacion de un medicamento para el tratamiento de infecciones virales susceptibles, por ejemplo, infecciones de hepatitis C cronicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19880100P | 2000-04-20 | 2000-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031572A1 true AR031572A1 (es) | 2003-09-24 |
Family
ID=22734903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101840A AR031572A1 (es) | 2000-04-20 | 2001-04-19 | Derivados de ribavirina, composiciones farmaceuticas y el uso de los mismos solo o en combinacion para la preparacion de medicamentos para erradicar hcv-arn en pacientes que tienen infeccion cronica de hepatitis c |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6924270B2 (es) |
| EP (1) | EP1282632A1 (es) |
| AR (1) | AR031572A1 (es) |
| AU (1) | AU2001255495A1 (es) |
| WO (1) | WO2001081359A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924270B2 (en) | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EP1294735A2 (en) | 2000-05-26 | 2003-03-26 | Novirio Pharmaceuticals Limited | Methods and compositions for treating flaviviruses and pestiviruses |
| US20060024270A1 (en) * | 2000-08-23 | 2006-02-02 | The New York Hospital Medical Center Of Queens | Compositions and methods for preventing or treating encephalitis with interferon |
| CN1516599A (zh) * | 2000-10-18 | 2004-07-28 | ���鹫˾ | 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法 |
| NZ537662A (en) * | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| MXPA04012802A (es) | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
| US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| CN100348607C (zh) | 2002-06-28 | 2007-11-14 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒科病毒感染的2’和3’－核苷前药 |
| WO2004004653A2 (en) * | 2002-07-02 | 2004-01-15 | Corcept Therapeutics, Inc. | Methods for treating psychosis associated with interferon-alpha therapy |
| US7824851B2 (en) * | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| WO2004052899A2 (en) * | 2002-12-12 | 2004-06-24 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
| CN100335492C (zh) * | 2002-12-23 | 2007-09-05 | 埃迪尼克斯(开曼)有限公司 | 生产3’－核苷前体药物的方法 |
| PT1633766T (pt) | 2003-05-30 | 2019-06-04 | Gilead Pharmasset Llc | Análogos de nucleósido fluorado modificado |
| ES2303132T3 (es) | 2003-08-07 | 2008-08-01 | Zymogenetics, Inc. | Preparaciones homogeneas de il-29. |
| NZ545159A (en) * | 2003-08-13 | 2009-03-31 | Smith Howard J & Ass Pty Ltd | Method of treating viral infections |
| CN1878783A (zh) * | 2003-09-11 | 2006-12-13 | 弗·哈夫曼-拉罗切有限公司 | 制备抗病毒核苷衍生物的方法 |
| US20050244423A1 (en) | 2004-04-02 | 2005-11-03 | Klucher Kevin M | Methods for treating viral infection using IL-28 and IL-29 cysteine mutants |
| RU2007102281A (ru) * | 2004-06-23 | 2008-07-27 | Айденикс (Кайман) Лимитед (Ky) | 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae |
| WO2006031725A2 (en) | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| DE602005015605D1 (de) * | 2004-10-29 | 2009-09-03 | Intercell Ag | Hcv impfstoff für chronische hcv patienten |
| EP2392590A3 (en) | 2005-11-11 | 2012-03-14 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7705138B2 (en) * | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7781576B2 (en) * | 2005-12-23 | 2010-08-24 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
| EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
| TW201031675A (en) | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| UY33311A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| CA2803093A1 (en) | 2010-06-24 | 2011-12-29 | Panmed Ltd. | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
| CN103179974A (zh) | 2010-10-05 | 2013-06-26 | 诺华有限公司 | 丙型肝炎病毒感染的新疗法 |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| US20130251678A1 (en) * | 2010-11-30 | 2013-09-26 | Novartis Ag | Bid dosage regimen for deb025 |
| CN103476409A (zh) | 2011-03-31 | 2013-12-25 | 诺华股份有限公司 | 治疗丙肝病毒感染的阿拉泊韦 |
| EP2696883A1 (en) | 2011-04-13 | 2014-02-19 | Novartis AG | Treatment of hepatitis c virus infection with alisporivir |
| EP2723337A1 (en) | 2011-06-23 | 2014-04-30 | Panmed Ltd. | Treatment of hepatitis c virus |
| SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
| MX2014003753A (es) | 2011-09-27 | 2014-05-01 | Novartis Ag | Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c. |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| WO2014122537A2 (en) | 2013-02-05 | 2014-08-14 | Genoscience Sa | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin |
| MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
| CN111320662B (zh) * | 2020-02-17 | 2022-11-25 | 南京医科大学 | 一类n-苄基取代的二脒那秦衍生物及其药物用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US3984396A (en) * | 1971-06-01 | 1976-10-05 | Icn Pharmaceuticals, Inc. | 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters |
| GB1482736A (en) | 1974-03-18 | 1977-08-10 | Icn Pharmaceuticals | 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives |
| US4544741A (en) | 1982-03-29 | 1985-10-01 | Robins Roland K | Azole dinucleotide compounds and methods for their production |
| US5674911A (en) | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
| US4925930A (en) | 1988-11-02 | 1990-05-15 | Nucleic Acid Research Institute | Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates |
| JPH07503851A (ja) * | 1992-02-10 | 1995-04-27 | インターフェロン・サイエンシズ、インコーポレイテッド | 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法 |
| GB9307043D0 (en) * | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US5981507A (en) | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| EP0942916A2 (en) | 1996-11-12 | 1999-09-22 | Medivir Aktiebolag | Nucleosides |
| US6403564B1 (en) * | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| NZ510811A (en) * | 1998-10-16 | 2003-06-30 | Schering Corp | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US6924270B2 (en) | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US6673775B2 (en) | 2001-04-18 | 2004-01-06 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
-
2001
- 2001-04-18 US US09/837,491 patent/US6924270B2/en not_active Expired - Fee Related
- 2001-04-18 AU AU2001255495A patent/AU2001255495A1/en not_active Abandoned
- 2001-04-18 EP EP01928662A patent/EP1282632A1/en not_active Withdrawn
- 2001-04-18 WO PCT/US2001/012760 patent/WO2001081359A1/en active Application Filing
- 2001-04-19 AR ARP010101840A patent/AR031572A1/es unknown
-
2004
- 2004-07-06 US US10/885,374 patent/US7115578B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20020055473A1 (en) | 2002-05-09 |
| WO2001081359A1 (en) | 2001-11-01 |
| US20050004053A1 (en) | 2005-01-06 |
| AU2001255495A1 (en) | 2001-11-07 |
| US6924270B2 (en) | 2005-08-02 |
| US7115578B2 (en) | 2006-10-03 |
| EP1282632A1 (en) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031572A1 (es) | Derivados de ribavirina, composiciones farmaceuticas y el uso de los mismos solo o en combinacion para la preparacion de medicamentos para erradicar hcv-arn en pacientes que tienen infeccion cronica de hepatitis c | |
| ES2566973T3 (es) | Uso de SNS-595 para tratar leucemia | |
| BR112015018751A2 (pt) | derivados de piridazinona macrocíclicos | |
| BR0211228A (pt) | Composto, composição farmacêutica e seus usos | |
| BR0315665A (pt) | Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| NO20052546L (no) | Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon. | |
| DE60239939D1 (de) | Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung | |
| AR044526A1 (es) | Compuestos triciclicos moduladores de receptor nuclear de hormonas esteroides, composiciones farmaceuticas que los comprenden y su uso para la fabricacion de un medicamento. | |
| ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
| AR056575A1 (es) | Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| ME00195B (me) | 4'-supstituisani nukleozidi | |
| CU20090209A7 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
| BRPI0408920A (pt) | difenilazetidinona com propriedades fisiológicas aperfeiçoadas, processo para a sua preparação, medicamentos contendo esses compostos e sua aplicação | |
| BRPI0308513B8 (pt) | micronizado cristalino de brometo de tiotrópio, processo para sua preparação, uso do mesmo, composição farmacêutica, pó para inalação, processo para sua preparação e cápsula que o contém | |
| CL2011001413A1 (es) | Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana. | |
| BR0016712A (pt) | Derivados do ácido n-benzil-indol-3-il-glioxìlico com efeito antitumor | |
| AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
| CA2430967A1 (en) | Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents | |
| NZ510811A (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| BR9911300A (pt) | Composto, composição farmacêutica, e, uso do composto | |
| BRPI0012475A (pt) | composto derivado de titânio, seu processo de preparação e utilização, bem como composição para uso oral compreendendo o mesmo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |